Načítá se...
Angiopoietin-like protein 3 blocks nuclear import of FAK and contributes to sorafenib response
BACKGROUND: Poor drug response of sorafenib is a major challenge which reduces clinical benefit of renal cell carcinoma (RCC) patients. It is therefore of great clinical significance to elucidate the underlying mechanism to restore the therapeutic response to sorafenib. METHODS: Angiopoietin-like pr...
Uloženo v:
| Vydáno v: | Br J Cancer |
|---|---|
| Hlavní autoři: | , , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Nature Publishing Group UK
2018
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6134083/ https://ncbi.nlm.nih.gov/pubmed/30033448 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41416-018-0189-4 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|